Pembrolizumab (Keytruda).

PubWeight™: 0.78‹?›

🔗 View Article (PMID 27398650)

Published in Hum Vaccin Immunother on July 11, 2016

Authors

Gerry Kwok1, Thomas C C Yau1, Joanne W Chiu1, Eric Tse1, Yok-Lam Kwong1

Author Affiliations

1: a Department of Medicine , Queen Mary Hospital , Hong Kong.

Articles cited by this

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95

Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42

Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00

PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08

PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89

T cell exhaustion. Nat Immunol (2011) 11.08

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49

Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94

Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol (2015) 5.95

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82

Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2015) 5.42

Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 4.94

The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med (2015) 4.24

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol (2015) 4.04

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res (2013) 3.48

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov (2014) 3.32

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature (2011) 3.22

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A (2008) 2.99

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med (2016) 2.54

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood (2008) 2.41

In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19

Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol (2015) 1.79

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol (2016) 1.70

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer (2016) 1.48

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol (2016) 1.28

PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria. Cell Rep (2013) 1.26

The tumour microenvironment in B cell lymphomas. Nat Rev Cancer (2014) 1.19

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med (2014) 1.09

Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09

2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol (2015) 1.08

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol (2015) 0.98

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer (2016) 0.96

Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget (2016) 0.96

Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes. Diabetes Care (2015) 0.90

Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma. Br J Haematol (2016) 0.80

Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation. Ann Hematol (2016) 0.77

Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. Melanoma Res (2015) 0.77